Case Report: Emergency CABG Following Failure of PTCA in a COVID-19 PatientCardiovascular Medicine Published on 2021-01-112022-10-31 Journal: Frontiers in Cardiovascular Medicine [Category] COVID-19, [키워드] acute respiratory distress acute respiratory syndrome adverse outcomes affecting ARDS CABG Cardiopulmonary cardiopulmonary bypass catheterization caused coronary artery dissection coronavirus disease Coronavirus-2 COVID-19 COVID-19 patient Cytokines storm develop Emergency exacerbate failure grafting higher risk Infection Intervention lack lung management protocol outbreak pandemic Patient public health emergency representing resulting SARS-CoV-2 syndrome unstable angina [DOI] 10.3389/fcvm.2020.620610 PMC 바로가기 [Article Type] Cardiovascular Medicine
Risk factors for mortality of critically ill patients with COVID-19 receiving invasive ventilationObservational Study Published on 2021-01-112022-10-04 Journal: International Journal of Medical Sciences [Category] MERS, 임상, [키워드] 28-day mortality 95% CI 95% confidence interval Admission age assessment Clinical data Comorbidity COVID-19 COVID-19 patient COVID-19 patients Cox regression analysis Critically ill Critically ill patient diabete Dyspnea Factor failure Fever hazard ratio high risk Hospital admission hypertension IMPROVE intubation invasive ventilation male median time Mortality non-survivor Non-survivors outcome patients with COVID-19 Primary outcome receiving Retrospective study risk factor secondary SOFA SOFA score survivor Symptom the median Ventilated was used with COVID-19 [DOI] 10.7150/ijms.50039 PMC 바로가기 [Article Type] Observational Study
Pilot trial of high-dose vitamin C in critically ill COVID-19 patientsResearch Published on 2021-01-092022-10-28 Journal: Annals of Intensive Care [Category] COVID-19, [키워드] 1:1 28-day mortality 95% CI acute respiratory syndrome assessment assigned benefit China clinical trial control group coronavirus Coronavirus disease 2019 COVID-19 COVID-19 patient critical COVID-19 patient Critically ill Critically ill patient effective failure HDIVC High-dose high-dose intravenous vitamin C High-dose vitamin C hospital ICU IL-6 IMPROVE IMVFD28 Infection Inflammation interleukin-6 intravenous invasive mechanical medication no difference Organ failure outbreak outcome Oxygenation PaO paO2/fiO2 Patient Placebo Primary outcome progression Randomized Randomly recruited reduce Result SARS-CoV-2 secondary severe acute respiratory syndrome coronavirus 2 severe coronavirus disease severe COVID-19 SOFA tested the placebo group Treatment treatment period Trial two group Vitamin C was performed water for injection with COVID-19 [DOI] 10.1186/s13613-020-00792-3 PMC 바로가기 [Article Type] Research
Development of a Predictive Model for Mortality in Hospitalized Patients With COVID-19Original Research Published on 2021-01-082022-10-31 Journal: Disaster Medicine and Public Health Preparedness [Category] COVID-19, MERS, [키워드] 95% confidence interval Accuracy Admission Analysis assessment AUC Clinical characteristics COVID-19 development diabete disease enrolled facilitate failure greater high mortality In-hospital death indicated lactate dehydrogenase Logistic Model Mortality multivariable multivariable analysis multivariable logistic regression nonsurvivor nonsurvivors novel corona virus Odds ratio outcome Patient patients with COVID-19 Predictive model Retrospective study risk risk factor Risk factors selected survivor Survivors were used [DOI] 10.1017/dmp.2021.8 PMC 바로가기 [Article Type] Original Research
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trialCOVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-01-062022-09-10 Journal: Trials [Category] MERS, 바이오마커, 임상, 치료제, [키워드] 1:1 24 hours 7-point ordinal scale acute respiratory distress acute respiratory distress syndrome Administered administration Admission Adult patient Adult patients Adverse Adverse drug reactions AEs age All trial participants all-cause mortality allergy Allogeneic ARDS assessment assigned baseline Biomarker blinded Blinding C-reactive protein carcinoma carcinoma in situ carried cellular chain change childbearing potential Chloroquine Clinical practice clinical status clinical trial coagulation test coagulation tests conducted Control control arm Course COVID COVID-19 CRF criteria CT scan cumulative incidence current Cytokines D-dimer Day death described determined by Diagnosis disease dissemination double-blind drug Duration ECMO Efficacy Efficacy and safety element eligible End endpoints enrolment EudraCT evaluate evaluate the effect event exclusion criteria Extracorporeal extracorporeal membrane oxygenation failure ferritin fibrosis FiO2 form GRADE grade 3 greater Haemodialysis handling hemofiltration history hospital Hospitalization hydroxy ICU ICU admission IMPROVE include inclusion criteria Informed consent intravenous Intravenous administration intravenous dose intubation Invasive mechanical ventilation invasive ventilation investigational medicinal product involved laboratory confirmation laboratory-confirmed SARS-CoV-2 infection lactation LDH less Level Local Lopinavir Lopinavir/ritonavir lung disorder lymphocyte marker Mechanical mechanical ventilation Medicine Medicines Mesenchymal stromal cells moderate to severe Mortality MSC negative pregnancy test neoplasm neutrophil neutrophil counts Non-invasive number objective occur off-label opinion Ordinal Scale organ oropharyngeal swab oropharyngeal swabs Other outcome oxygen oxygen saturation Oxygen therapy PaO2 PaO2/FiO2 ratio parameters participant Patient PCR percentage Placebo polymerase chain reaction Pregnancy primary endpoint product Production profile progression protocol Pulmonary embolism pulmonary fibrosis Pulmonary function tests randomised randomised controlled trial randomization Randomized Randomly Rapid antigen tests reaction receive recruitment Registered Remdesivir report respiratory Respiratory distress syndrome Resuscitation Ritonavir SAEs Sample size SARS-COV-2 infection secondary Secondary endpoints Sequential Organ Failure Assessment Serious Adverse Events SOFA Spain specificity specimen Sponsor Standard of care status stromal cell stromal cells Study protocol subpopulations supplemental oxygen supplementary material syndrome the cell the disease the patient the primary endpoint the WHO time Tocilizumab Tolerability Treatment treatment arm treatment for COVID-19 treatment group Treatment protocol Trial trial participant Trial registration unit website women worldwide pandemic written consent [DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter
A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study)Kampo 의약품을 사용한 COVID-19 예방에 대한 다기관, 무작위 대조 시험(RCT) 연구 프로토콜의 구조화된 요약(예방 연구에 의한 전염병에 대한 일본의 통합 관리: IMJEDI P1 연구)Letter Published on 2021-01-062022-08-31 Journal: Trials [Category] MERS, 임상, 치료제, [키워드] 1:1 administration age allergic Analysis appearance Arm ARMS assumed Asymptomatic balancing Blinding body temperature calculated capture cardiovascular disease Chain Reaction clinical clinical trials cloud condition Control control group cough COVID-19 diabetes disappearance dissemination doctor dosage dropout rate drug edema effective element Endpoint exclusion criteria failure Fever Final final analysis final analysis) Frequency group hands healthy history hospital Hospitalization hypertension hypokalaemia Hypothesis ICU Immunosuppressant immunosuppressants incidence of COVID-19 incidence rate incidence rates include inclusion criteria Infection infection rate Inflammation interim analysis interstitial pneumonia intervention group investigator Japan Japanese Kampo Kampo medicines liver dysfunction lung malaise management mechanical ventilation Medicine number numbness objective observation period oral administration oral administration) outcome package parallel-group participant Patient PCR PCR positive per day Period pharmaceutical Placebo placebo group Placebo tablets positive result power power of 80% pregnant Prevent Prophylactic prophylactic study protocol randomised Randomized Randomized controlled trial RCT receive recruited Registered Registration registry required Research respiratory respiratory diseases respiratory inflammation risk factor Risk factors Safety Sample size SARS-CoV-2 RNA secondary Secondary outcomes Shock Shortness of breath significantly skin rash sputum study drug study period Study protocol supplementary material Symptom Symptoms symptoms of COVID-19 Tablet Taking Taste the placebo group Trial Trial registration Two-arm university upper respiratory verification Viral viral infection Vital website [DOI] 10.1186/s13063-020-04939-2 PMC 바로가기 [Article Type] Letter
Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm중증 COVID-19 환자의 심부전 치료제: 사이토카인 폭풍 진정Review Published on 2021-01-062022-09-10 Journal: Cardiovascular Drugs and Therapy [Category] MERS, SARS, 치료제, [키워드] accumulating acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 cardiovascular system convergence coronavirus coronavirus disease COVID-19 COVID-19 in patient cytokine Cytokine storm drug Economy Evidence failure focus Health heart heart failure induce mechanism myocardial damage pandemic pathophysiologic process pathophysiological patients with COVID-19 point of convergence populations presenting progression pulmonary injury respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus storm target populations therapeutic target therapeutic targets therapy Treatment Trigger [DOI] 10.1007/s10557-020-07120-8 PMC 바로가기 [Article Type] Review
Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery코로나바이러스 질병 2019 환자의 시험에 대한 핵심 결과 측정: 호흡 부전, 다기관 부전, 숨가쁨 및 회복Clinical Investigations Published on 2021-01-052022-09-11 Journal: Critical Care Medicine [Category] 임상, [키워드] 5-point Likert scale absence activities activity applicability assessment capture Care clinical clinical care clinical trial Consensus Consistency content content validity core coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019) country Critical care de novo Decision-making defined Digital Digital Content domain Evidence extreme failure feasible fluctuation Health Health Organization Inclusion Infection International measure Measures Medical Research Council Mortality multiple organ failure Organ failure outcome outcome measure outcome measures participant Patient patients Pragmatic professionals recall respiratory Respiratory failure Respiratory Support scale Sepsis Sequential Organ Failure Assessment severity Shortness of breath Symptoms text Trial Validity World Health Organization [DOI] 10.1097/CCM.0000000000004817 PMC 바로가기 [Article Type] Clinical Investigations
Neglected tropical diseases activities in Africa in the COVID-19 era: the need for a “hybrid” approach in COVID-endemic timesCommentary Published on 2021-01-042022-10-29 Journal: Infectious Diseases of Poverty [Category] COVID-19, [키워드] activities activity acute respiratory syndrome African approach Behaviour change communities Community coronavirus coronavirus disease Coverage COVID-19 disease Drug administration Endemic ENhance facilitate failure Health health systems hygiene Intervention management Masks Mass drug administration MDA Medicine morbidity Morbidity management Neglected neglected tropical diseases NTD pandemic physical distancing promoted reduce risk risk of COVID-19 Sanitation and hygiene SARS-CoV-2 Spread Support target Transmission tropical virus water [DOI] 10.1186/s40249-020-00791-3 PMC 바로가기 [Article Type] Commentary
Unexpectedly High Frequency of Enterococcal Bloodstream Infections in Coronavirus Disease 2019 Patients Admitted to an Italian ICU: An Observational StudyObservational Study Published on 2021-01-012022-10-05 Journal: Critical Care Medicine [Category] 임상, [키워드] 48 hour 95% CI accounted assessment Bacteria bloodstream bloodstream infection calculated competing coronavirus disease Coronavirus disease 2019 cumulative probability death discharge eight Enterococcus events failure Frequency greater ICU ICU admission Infection infectious agent interquartile range Invasive mechanical ventilation isolate Italian Italy limitation Luigi measurement median median time Patient patients prevalent recorded required severe coronavirus disease Transmission [DOI] 10.1097/CCM.0000000000004748 PMC 바로가기 [Article Type] Observational Study